Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity

Natural killer (NK) cells serve as important effectors for antitumor immunity, and CD56+CD45+ NK cells can be routinely derived from human embryonic stem cells (hESCs). However, little is know about the ability of hESC-derived NK cells to mediate an effective in vivo antitumor response. Using biolum...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 113; no. 24; pp. 6094 - 6101
Main Authors Woll, Petter S., Grzywacz, Bartosz, Tian, Xinghui, Marcus, Rebecca K., Knorr, David A., Verneris, Michael R., Kaufman, Dan S.
Format Journal Article
LanguageEnglish
Published Washington, DC Elsevier Inc 11.06.2009
Americain Society of Hematology
American Society of Hematology
SeriesHematopoiesis and Stem Cells
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Natural killer (NK) cells serve as important effectors for antitumor immunity, and CD56+CD45+ NK cells can be routinely derived from human embryonic stem cells (hESCs). However, little is know about the ability of hESC-derived NK cells to mediate an effective in vivo antitumor response. Using bioluminescent imaging, we now demonstrate that H9 line hESC-derived NK cells mediate effective clearance of human tumor cells in vivo. In addition to increased in vitro killing of diverse tumor targets, the in vivo tumor clearance by H9 hESC-derived NK cells was more effective compared with NK cells derived from umbilical cord blood (UCB). Phenotypic analysis demonstrates the hESC-derived NK cells are uniformly CD94+CD117low/−, an NK-cell population characterized by potent cytolytic activity and thus more competent to mediate tumor clearance. These studies demonstrate that hESCs provide an important model to study human lymphocyte development and may serve as a novel source for antitumor immunotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2008-06-165225